A Phase 1 Study of JNJ-87562761 in Relapsed/Refractory Multiple Myeloma
87562761MMY1001
Phase 1 other active
Quick answer
A Phase 1 Study of JNJ-87562761 in Relapsed/Refractory Multiple Myeloma for Relapsed/Refractory Multiple Myeloma is a Phase 1 program (other) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 1
- Modality
- other
- Status
- active